List of Coreg Cr drug patents
Coreg Cr is owned by Woodward.
Coreg Cr contains Carvedilol Phosphate.
Coreg Cr has a total of 4 drug patents out of which 0 drug patents have expired.
Coreg Cr was authorised for market use on 20 October, 2006.
Coreg Cr is available in capsule, extended release;oral dosage forms.
Coreg Cr can be used as treatment of hypertension; treatment of congestive heart failure.
The generics of Coreg Cr are possible to be released after 11 March, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7268156 | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Jun, 2023
(4 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7268156
(Pediatric) | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Dec, 2023
(10 months from now) | |
| US8101209 | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Sep, 2025
(2 years from now) | |
|
US8101209
(Pediatric) | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Mar, 2026
(3 years from now) | |
Drugs and Companies using CARVEDILOL PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: Treatment of hypertension; Treatment of congestive heart failure
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
COREG CR family patents
10
United States
8
China
5
Korea, Republic of
5
Japan
4
European Union
3
Canada
2
Brazil
2
South Africa
2
Australia
2
France
2
Israel
2
Mexico
1
Hong Kong
1
Norway
1
Spain
1
New Zealand
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic